mifepristone has been researched along with Adrenocorticotropic Hormone, Inappropriate Secretion in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (80.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castinetti, F | 1 |
| Chakrabarti, J; Churko, J; Eschbacher, J; Greenstein, AE; Little, AS; Livolsi, A; Mallick, S; Moraitis, AG; Pond, KW; Thorne, CA; Yuen, KCJ; Zavros, Y | 1 |
| Biller, BMK; Tritos, NA | 1 |
| Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS | 1 |
| Fleseriu, M; Petersenn, S | 2 |
| Cohan, P | 1 |
| Cannavo, S; Ferrau, F; Trimarchi, F | 1 |
| Buchfelder, M; Findling, JW; Fleseriu, M; Gross, C; Koch, CA; Schlaffer, SM | 1 |
| Hamrahian, AH; Hoffman, AR; Yuen, KC | 1 |
| Biller, BM; Tritos, NA | 1 |
| Fleseriu, M | 1 |
| Alexandraki, KI; Grossman, AB | 1 |
| Barahona Constanzo, MJ; del Pozo Picó, C | 1 |
| Carmichael, JD; Fleseriu, M | 1 |
11 review(s) available for mifepristone and Adrenocorticotropic Hormone, Inappropriate Secretion
| Article | Year |
|---|---|
How best to monitor the specific side effects of medical treatments of Cushing's disease.
Topics: Humans; Metyrapone; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Retrospective Studies | 2022 |
Advances in the Medical Treatment of Cushing Disease.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Cabergoline; Endocrinology; Humans; Mifepristone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin; Treatment Outcome | 2020 |
New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Hormone Antagonists; Humans; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Pituitary Neoplasms | 2013 |
Pasireotide and mifepristone: new options in the medical management of Cushing's disease.
Topics: Adrenocorticotropic Hormone; Humans; Mifepristone; Pituitary ACTH Hypersecretion; Receptors, Glucocorticoid; Somatostatin | 2014 |
AACE/ACE Disease State Clinical Review: Medical Management of Cushing Disease.
Topics: Adrenocorticotropic Hormone; Cabergoline; Drug Therapy, Combination; Ergolines; Humans; Ketoconazole; Mifepristone; Pituitary ACTH Hypersecretion; Somatostatin | 2014 |
Cushing's disease.
Topics: Adrenocorticotropic Hormone; Animals; Hormone Antagonists; Humans; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; Quality of Life | 2014 |
Medical treatment of Cushing disease: new targets, new hope.
Topics: Cytochrome P-450 Enzyme Inhibitors; Hormone Antagonists; Hormones; Humans; Imidazoles; Mifepristone; Pituitary ACTH Hypersecretion; Pyridines; Somatostatin | 2015 |
Medical therapy of Cushing's disease: where are we now?
Topics: Dopamine Agonists; Humans; Hydrocortisone; Ketoconazole; Metyrapone; Mifepristone; Mitotane; Pituitary ACTH Hypersecretion; Somatostatin | 2010 |
Medical management of Cushing's disease: what is the future?
Topics: Aminoglutethimide; Dopamine Agonists; Drug Therapy, Combination; Etomidate; Humans; Ligands; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Gland; PPAR gamma; Receptors, Glucocorticoid; Receptors, Somatostatin; Somatostatin | 2012 |
New prospects for drug treatment in Cushing disease.
Topics: Adenoma; Adrenocorticotropic Hormone; Animals; Cabergoline; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Ergolines; Etomidate; Humans; Hydrocortisone; Imidazoles; Ketoconazole; Metyrapone; Mice; Mifepristone; Mitotane; Multicenter Studies as Topic; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Pyridines; Rats; Somatostatin; Therapies, Investigational; Tretinoin | 2012 |
Mifepristone: is there a place in the treatment of Cushing's disease?
Topics: Adrenal Glands; Animals; Drug Delivery Systems; Drug-Related Side Effects and Adverse Reactions; Hormone Antagonists; Humans; Mifepristone; Pituitary ACTH Hypersecretion | 2013 |
1 trial(s) available for mifepristone and Adrenocorticotropic Hormone, Inappropriate Secretion
| Article | Year |
|---|---|
Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone.
Topics: Adenoma; Adrenocorticotropic Hormone; Adult; Corticotrophs; Female; Hormone Antagonists; Humans; Hydrocortisone; Magnetic Resonance Imaging; Male; Middle Aged; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Prospective Studies; Receptors, Glucocorticoid | 2014 |
3 other study(ies) available for mifepristone and Adrenocorticotropic Hormone, Inappropriate Secretion
| Article | Year |
|---|---|
Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Topics: Adrenocorticotropic Hormone; Corticotrophs; Hedgehog Proteins; Humans; Mifepristone; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Receptors, Glucocorticoid | 2023 |
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult | 2017 |
Adrenocorticotropin responsiveness to acute octreotide administration is not affected by mifepristone premedication in patients with Cushing's disease.
Topics: Adrenocorticotropic Hormone; Down-Regulation; Female; Hormone Antagonists; Humans; Male; Middle Aged; Mifepristone; Octreotide; Pituitary ACTH Hypersecretion | 2014 |